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ABSTRACT
Aims To compare the population proportion at high risk 
of cardiovascular disease (CVD) using the Norwegian 
NORRISK 1 that predicts 10- year risk of CVD mortality 
and the Norwegian national guidelines from 2009, with 
the updated NORRISK 2 that predicts 10- year risk of both 
fatal and non- fatal risk of CVD and the Norwegian national 
guidelines from 2017.
Methods We included participants from the Norwegian 
population- based Tromsø Study (2015–2016) aged 
40–69 years without a history of CVD (n=16 566). The 
total proportion eligible for intervention was identified 
by NORRISK 1 and the 2009 guidelines (serum total 
cholesterol ≥8 mmol/L, systolic blood pressure ≥160 mm 
Hg or diastolic blood pressure ≥100 mm Hg) and 
NORRISK 2 and the 2017 guidelines (serum total 
cholesterol ≥7 mmol/L, low density lipoprotein (LDL) 
cholesterol ≥5 mmol/L, systolic blood pressure ≥160 mm 
Hg or diastolic blood pressure ≥100 mm Hg).
Results The total proportion at high risk as defined by a 
risk score was 12.0% using NORRISK 1 and 9.8% using 
NORRISK 2. When including single risk factors specified by 
the guidelines, the total proportion eligible for intervention 
was 15.5% using NORRISK 1 and the 2009 guidelines and 
18.9% using NORRISK 2 and the 2017 guidelines. The 
lowered threshold for total cholesterol and specified cut- 
off for LDL cholesterol stand for a large proportion of the 
increase in population at risk.
Conclusion The population proportion eligible for 
intervention increased by 3.4 percentage points from 2009 
to 2017 using the revised NORRISK 2 score and guidelines.
INTRODUCTION
Cardiovascular disease (CVD) is a leading 
cause of death and disability worldwide and 
an economic burden for the society, thereby 
calling for an active preventive approach.1 
Cardiovascular risk prediction tools have been 
developed to objectively estimate risk and to 
guide clinical decision- making on initiating, 
intensifying or discontinuing medical treat-
ment for CVD primary prevention.2 The Fram-
ingham Risk Score, developed from the Fram-
ingham Heart Study in the USA, was the first 
and most broadly used risk score, and several 
other risk scores have been developed later.3 
The European guidelines for CVD primary 
prevention included the Framingham Risk 
Score in 1994 and 1998,4 5 but studies found 
the risk score to overestimate risk in European 
populations.6 7 The Systematic Coronary Risk 
Evaluation (SCORE) risk chart was developed 
from European cohort studies, and separate 
Key questions
What is already known about this subject?
 ► Risk assessment tools and primary prevention guide-
lines for cardiovascular disease are used to identify 
individuals eligible for preventive interventions.
 ► There is a need to balance risk of overtreatment, 
healthcare cost and potential side effects versus 
undertreatment.
What does this study add?
 ► We demonstrate how change of cardiovascular risk 
assessment tool and updated guidelines increase 
the population proportion eligible for preventive 
interventions.
How might this impact on clinical practice?
 ► New insights into the impact of risk assessment 
scoring to identify individuals at risk and accurate 
estimates of the proportion of the total population 





ctober 12, 2021 at H














2 Nilsen A, et al. Open Heart 2021;8:e001777. doi:10.1136/openhrt-2021-001777
risk charts have been developed for low- risk and high- risk 
regions in Europe.8 CVD primary prevention guidelines 
highlight the use of cardiovascular risk assessment tools to 
identify high- risk individuals and to indicate when to start 
treatment, through risk assessment scoring and treatment 
guidelines for single risk factors.9 10 In Norway, the 2009 
guidelines for CVD primary prevention11 recommended 
the use of a risk assessment tool to identify high- risk indi-
viduals and proposed NORRISK 1, a national calibrated 
variant of the SCORE prediction model to predict 10- year 
risk of fatal CVD.12 The guideline revision in 201713 recom-
mended the updated risk assessment tool NORRISK 2 to 
predict 10- year risk of both fatal and non- fatal CVD.14
Guideline updates will change the definition of the 
population at risk. Lowering the threshold for defining 
individuals at high risk and eligible for primary preven-
tion of CVD causes a larger proportion of individuals in 
need of lifestyle changes and potentially drug treatment 
with antihypertensives and/or lipid- lowering drugs. 
However, a change in threshold can also result in the 
potential of preventing more fatal and non- fatal events 
of CVD. There is a need for balancing between the risk 
of undertreatment with risk of disease or death and over-
treatment, medication- related side effects, financial cost 
and healthcare priorities.15–17 The aim of this study was 
to compare the population proportion at risk and eligi-
bility for intervention as defined by NORRISK 1 and the 
Norwegian national guidelines from 2009 with NORRISK 
2 and the national guidelines from 2017 using a Norwe-
gian population- based sample.
METHODS
Study population
The Tromsø Study is an ongoing population- based cohort 
study in the municipality of Tromsø, Northern Norway. The 
study includes seven surveys conducted between 1974 and 
2016 (Tromsø 1–7). Both total birth cohorts and representa-
tive samples of the population have been invited, and a total 
of 45 473 women and men have participated in one or more 
surveys (attendance 65%–79%).18 Data collection includes 
questionnaires, interviews, biological sampling and clinical 
examinations. In this study, we included participants from 
Tromsø 7 (2015–2016), to which all inhabitants aged 40 
years or older (n=32 591) were invited, and 21 083 women 
and men participated (65%). We excluded participants 
70 years and older (n=3437), those with previous myocar-
dial infarction (MI) or stroke (n=704) and those without 
valid data for NORRISK 1 and NORRISK 2 risk calculation 
(n=376), leaving 16 566 participants for the current analysis. 
All participants gave written informed consent. The study 
was approved by the Regional Committee for Medical and 
Health Research Ethics North (reference 1778/2015).
Case validation
Cases of MI and stroke were recorded and validated 
from study entry until 31 December 2014 by the Tromsø 
Study CVD registry and were available for all participants 
attending Tromsø 7 and one or more of the previous six 
surveys. Adjudication of hospitalised and out- of- hospital 
events was performed by an independent end- point 
committee reviewing medical records and medical notes, 
autopsy records and death certificates. The national 
unique 11- digit identification number allowed linkage to 
national and local diagnosis registries. Cases of MI and 
stroke were identified by linkage to the discharge diag-
nosis registry at the University Hospital of North Norway, 
the only hospital in the area, with search for Interna-
tional Classification of Diseases described in detail else-
where.19 Due to the lack of validated endpoints after 2014 
and among participants attending Tromsø 7 only, we also 
used self- reported MI or stroke (‘Have you had a heart 
attack?’ and ‘Have you had a stroke?’) to exclude individ-
uals with previous MI or stroke.
Measurements
Self- reported data on smoking, diabetes, family history of 
coronary heart disease (CHD) and use of lipid- lowering 
and antihypertensive medication were collected via ques-
tionnaires. For medication use, a combination of a ques-
tion (‘Do you use blood pressure lowering drugs?’ and 
‘Do you use lipid- lowering drugs?’) and information from 
a self- reported written list of brand names of regularly 
used medication (antihypertensives (ATC codes C02, 
C03, C07, C08 and C09) and lipid- lowering drugs (ATC 
code C10) was used. Blood pressure was measured on 
the right arm of all participants (unless in circumstances 
where this was not possible) three times at 1 min intervals 
after 2 min seated rest by a Dinamap ProCare 300 monitor 
(GE Healthcare, Norway), and the mean of the two final 
readings was used in the analysis. Non- fasting venous 
blood samples were collected with standard methods, 
and the samples were analysed within 48 hours for total, 
LDL and high density lipoprotein (HDL) cholesterol by 
enzymatic colorimetric methods (with Roche Diagnos-
tics, Mannheim, Germany) and glycated haemoglobin 
(HbA1c) by high- performance liquid chromatography 
(with Tosoh G8, Tosoh Bioscience, San Francisco, USA) 
at the department of laboratory medicine, University 
Hospital of North Norway. Trained personnel performed 
all measurements.
NORRISK 1 and the 2009 guidelines
The multivariable CVD risk assessment tool NORRISK 1 is 
a Norwegian adaption of the European SCORE model and 
predicts 10- year risk (%) of death due to atherosclerotic 
CVD in individuals aged 40–69 years.12 Together with the 
Norwegian guidelines from 2009, NORRISK intended to 
identify high- risk individuals and guide decision- making 
in CVD primary prevention. The 10- year risk estimation 
is based on age, sex, systolic blood pressure, serum total 
cholesterol and daily smoking habits. Additional risk 
factors HbA1c levels and first- degree family member with 
a history of premature CHD were used to recalculate risk 
with specific cut- offs.11 12 Age- specific thresholds are set 
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antihypertensives and/or lipid- lowering drugs, where 
indication to initiate treatment is set to NORRISK 1 score: 
40–49 years score ≥1%, 50–59 years score ≥5% and 60–69 
years score ≥10%. The 2009 guideline defined individ-
uals with elevated values of total cholesterol ≥8 mmol/L, 
systolic blood pressure ≥160 mm Hg or diastolic blood 
pressure ≥100 mm Hg to be eligible for intervention 
regardless of their NORRISK 1 score. In this study, we 
also calculated the proportion eligible for intervention 
based on the international definition of hypertension: 
blood pressure ≥140/90 mm Hg.
NORRISK 2 and the 2017 guidelines
In 2017, the revised national guidelines for CVD preven-
tion were introduced, and an updated and revised risk 
assessment tool, NORRISK 2, was presented to identify 
high- risk individuals eligible for intervention.13 NORRISK 
2 predicts the 10- year risk (%) of incident MI and stroke 
combined, including both non- fatal and fatal events of 
CHD and stroke. The 10- year risk estimation is based 
on age, sex, systolic blood pressure, serum total choles-
terol, daily smoking habits, first- degree family member 
with a history of premature MI (before the age of 60 
years), low serum HDL cholesterol based on sex specific 
cut- off values (1.0 mmol/L in men and 1.3 mmol/L in 
women) and use of antihypertensives (where current use 
increases the score). Selmer et al14 suggest age- specific 
thresholds in age groups 45–54, 55–64 and 65–74 years 
to determine whether an individual is at low, medium or 
high risk of CVD. Elevated values on single risk factors, 
that is, serum total cholesterol ≥7 mmol/L, LDL choles-
terol ≥5 mmol/L (does not apply for women over 50 
years), systolic blood pressure ≥160 mm Hg or diastolic 
blood pressure ≥100 mm Hg, identify individuals eligible 
for intervention regardless of the NORRISK 2 score. 
In addition, in individuals with diabetes, LDL choles-
terol ≥2.5 mmol/L and blood pressure ≥140/90 mm Hg 
indicate eligibility for intervention.16 In this study, we 
also calculated the proportion eligible for intervention 
by the international definition of hypertension: blood 
pressure ≥140/90 mm Hg. Additional risk factors (South 
Asian ethnicity and diagnosis of rheumatoid arthritis) 
can be used to recalculate the risk score, with specific cut- 
offs. Abdominal obesity, mental strain and stress are addi-
tional risk factors without a specific cut- off value.13 In this 
study, we did not use the proposed additional risk factors 
to recalculate the NORRISK 2 score.
Statistics
We calculated means and proportions of cardiovascular 
risk factors and sociodemographic factors including self- 
reported education and cardiovascular risk including 
measured body mass index (BMI) (normal, overweight 
and obesity defined as <25, 25–29.9 and 30 kg/m2, 
respectively) and waist circumference (obesity defined 
as ≥88 and≥102 cm in women and men, respectively) and 
self- reported current diabetes and physical activity level 
to present study population characteristics (table 1). 
We calculated the proportion of participants eligible 
for intervention according to NORRISK 1 and the 2009 
guidelines and NORRISK 2 and the 2017 guidelines 
(table 2), overall and stratified by sex and age groups. 
In addition, we calculated the proportion eligible for 
intervention using NORRISK 1 without the additional 
risk factors HbA1c level and family history of premature 
CHD (online supplemental table 1). We also recalcu-
lated the proportion in need of intervention with systolic 
blood pressure ≥140 mm Hg and diastolic blood pres-
sure ≥90 mm Hg as cut- off (online supplemental table 
2). To compare sex differences, we used t- tests for contin-
uous variables and χ2 tests for categorical variables and 
McNemar test for pairwise data comparing differences in 
risk score. Results were considered statistically significant 
when a p value less than 5% was attained. To visualise the 
overlap of high- risk participants defined by NORRISK 1 
and NORRISK 2 scores, as well as risk score with addi-
tional risk factors from the concurrent guidelines, we 
present area- proportional Venn diagrams (figure 1), 
overall and by sex. All analyses were performed using 
Stata V.16 (StataCorp, 2019; Stata Statistical Software).
RESULTS
Study population and CVD risk factors
Study population characteristics are presented in table 1. 
Mean age was 53 years for both sexes. Compared with 
women, men had higher LDL cholesterol, blood pres-
sure, prevalence of obesity (BMI >30 kg/m2), diabetes, 
sedentary lifestyle and use of lipid- lowering drugs and 
antihypertensives but lower HDL cholesterol, prevalence 
of smoking, abdominal obesity and a lower proportion 
with higher education.
NORRISK 1 versus NORRISK 2
The total proportion at high risk (ie, eligible for interven-
tion) defined by risk score only was 12.0% for NORRISK 
1 and 9.8% for NORRISK 2 (table 2). The proportion of 
high- risk individuals using NORRISK 1 was 8.6% calcu-
lated without the additional risk factors HbA1c and family 
history (online supplemental table 1). In all age groups, 
a higher proportion of men than women was defined as 
high- risk individuals (p<0.001) (table 2). Among men 
aged 40–49 years, a larger proportion was identified as 
high risk using NORRISK 1 compared with NORRISK 2 
(p<0.001), whereas in men aged 50–59 years, more men 
were identified as high risk using NORRISK 2 (p<0.001).
Total proportion eligible for intervention
The total proportion eligible for intervention identified 
by risk score or elevated values for single CVD risk factors 
was 3.4 percentage points higher using NORRISK 2 and the 
2017 guidelines compared with NORRISK 1 and the 2009 
guidelines (18.9% vs 15.5%). The total proportion eligible 
for intervention was higher using NORRISK 2 and the 2017 
guidelines in both sexes and all age groups, except among 
men aged 40–49 years (table 2). In women, the propor-
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points from 6.8% to 9.8%, and the increase among men was 
3.8 percentage points from 25.6% to 29.4% by NORRISK 
1 and the 2009 guidelines, compared with NORRISK 2 
and the 2017 guidelines, respectively. Overall, participants 
defined as being at low risk by risk score were to a greater 
extent identified as eligible for intervention by single risk 
factors when using the 2017 guidelines compared with the 
2009 guidelines. This was due to change in the cut- off value 
for serum total cholesterol and the introduction of a spec-
ified value for LDL cholesterol. One percent of the partic-
ipants with low risk by NORRISK 1 had total cholesterol 
above the threshold of ≥8 mmol/L, whereas the lowering 
of the threshold in the 2017 guideline to ≥7 mmol/L 
increased the proportion to 2.8% in individuals with low risk 
by NORRISK 2. Specifying a threshold for LDL cholesterol 
to ≥5 mmol/L in the 2017 guideline identified 3.6% indi-
viduals above threshold among individuals identified as low 
risk by NORRISK 2. Among participants defined as being 
at low risk by NORRISK 1, systolic blood pressure identified 
an additional 2.7% of the study population as high risk with 
the 2009 guideline, and 3.1% of participants defined as low 
risk by NORRISK 2 were identified as being at high risk by 
the 2017 guidelines. When including the diabetes- specific 
threshold in the 2017 guidelines for those with self- reported 
diabetes, 2.7% had LDL cholesterol ≥2.5 mmol/L, and 0.9% 
had blood pressure ≥140/90 mm Hg but were defined as low 
risk by NORRISK 2. A larger proportion of women compared 
with men was identified as eligible for intervention by single 
risk factors only using the 2009 guidelines, while applying 
single risk factors only to the 2017 guidelines identified a 
Figure 1 Venn diagram presenting the overlap of identification of high- risk participants defined by NORRISK 1 (red circle) and 
NORRISK 2 (green circle) in the total sample (purple square) (panel A) and NORRISK 1 and NORRISK 2 combined with single 
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higher proportion of men than women eligible for interven-
tion. When we recalculated the total proportion eligible for 
intervention based on systolic blood pressure ≥140 mm Hg 
and diastolic blood pressure ≥90 mm Hg, we found 29.3% 
based on NORRISK 1 and the 2009 guidelines and 32.4% 
using NORRISK 2 and the 2017 guidelines (online supple-
mental table 2).
Overlap between risk scores only and risk scores and the 
guidelines combined
Among individuals identified as high risk by risk score only, 
NORRISK 1 identified in total 12.0% (2.2% of women and 
23.3% of men) as high risk, while NORRISK 2 identified in 
total 9.8% (2.4% of women and 18.3% of men) as high risk. 
The overlapping proportion identified as high risk in both 
risk scores was in total 5.4% (0.9% of women and 10.7% of 
men). Combining NORRISK 1 and the 2009 guidelines, 
15.5% in total (6.8% women and 25.6% men) was identified 
as eligible for intervention, while when using NORRISK 2 
and the 2017 guidelines, the proportion was 18.9% in total 
(9.8% women and 29.4% men). Overall, the overlapping 
proportion of 10.7% (5.1% women and 17.3% men) was 
identified as eligible for intervention in both risk scores with 
their respective guidelines (figure 1).
DISCUSSION
In this study, we compared the proportion at high CVD risk 
and eligible for intervention using two consecutive versions 
of guidelines and risk assessment tools in a Norwegian 
general population of women and men aged 40–69 years. 
The main finding is that the proportion eligible for inter-
vention increased from 15.5% using the risk assessment tool 
NORRISK 1 and the 2009 guidelines to 18.9% using the 
revised NORRISK 2 and the 2017 guidelines.
Change in cardiovascular risk assessment tool
The proportion of high- risk individuals defined by risk score 
only was lower using the updated NORRISK 2 compared 
with the previous NORRISK 1. This can be explained by the 
fundamental differences in the risk scores, as they measure 
different endpoints and thus are not directly comparable. 
NORRISK 1 predicts 10- year risk of fatal CVD, whereas 
NORRISK 2 predicts the 10- year risk of MI, stroke and fatal 
CVD.12 14 The European guidelines for CVD primary preven-
tion encourage the calibration of risk assessment tools to the 
target population by adjusting for secular changes in risk 
factor levels and CVD mortality.20 A reduction over time in the 
major CVD risk factors serum total cholesterol, blood pres-
sure and smoking in the general population has been shown 
both in large international studies21 22 and in the Tromsø 
Study population,19 23 24 and we have previously demon-
strated a decline in total CVD risk in the Tromsø Study25 
similar to findings from the UK26 and the USA.27 Further, 
there has been a major decline in mortality and morbidity 
of CVD in Norway.28 The reduction in risk factors, morbidity 
and mortality over time can explain the lower proportion 
eligible for intervention by the updated risk assessment tool 
NORRISK 2. NORRISK 1 is a national calibrated version 
of the European SCORE algorithm, based on national 
mortality rates from 1993 to 2003, and mean level risk 
factors from Norwegian Health Surveys from 2000 to 2003,12 
while NORRISK 2 is based on the 10- year follow- up of a large 
population- based cohort (Cohort of Norway (CONOR)) 
through linkage to the Cardiovascular Disease in Norway 
(CVDNOR) project, a database of CVD hospital discharge 
diagnoses and mortality in Norway in 1994–2009.14 Another 
explanation of this finding can be the use of additional risk 
factors in our analysis, where we included additional risk 
factors in the calculation of NORRISK 1 (HbA1c levels and 
family history of CHD) and did not include the additional 
risk factors (rheumatoid arthritis, South Asian ethnicity, 
abdominal obesity and/or mental stress) in the calculation 
of NORRISK 2. A recent study found NORRISK 2 to under-
estimate CVD risk in South Asians and proposed an update 
(NORRISK 2-SADia) improving the predictions of 10- year 
risk in this population.29 In our study, valid data regarding 
the proposed additional risk factors with specified cut- offs 
(ethnicity and diagnosis of rheumatoid arteritis) were not 
available.30 Almost half of the study population had abdom-
inal obesity, and in real patient consultations, this could 
lead to a higher proportion at high risk using NORRISK 2. 
However, this risk factor is without a multiplication factor 
and hence not used to calculate the proportion eligible for 
intervention in this study.
Single risk factors defined in treatment guidelines
In this study, we found that the updated risk score with addi-
tional guidelines increased the proportion of participants 
eligible for intervention, where the decrease in threshold for 
total cholesterol levels and a defined value of LDL choles-
terol stand for a large proportion of this increase. The impact 
on the risk of CVD by lowering cholesterol levels is well 
known. A lowering of LDL cholesterol levels by 1 mmol/L 
corresponds to a 20%–25% reduction in non- fatal MI and 
death due to CVD.10 Our findings are in line with a study 
from Denmark where the authors found that the updated 
2019 European Society of Cardiology/European Athero-
sclerosis Society (ESC/EAS) guidelines doubled the propor-
tion of individuals eligible for statin therapy compared with 
the previous guidelines,31 findings that are similar to other 
studies.32 33
For blood pressure, there was no difference in threshold 
between the 2009 and 2017 guidelines where systolic blood 
pressure ≥160 mm Hg and diastolic blood pressure ≥100 mm 
Hg urge immediate start of pharmacological treatment 
(regardless of NORRISK score), in line with the European 
ESC/EAS guidelines.34 In the American College of Cardi-
ology/American Heart Association (ACC/AHA) guidelines, 
the recommendation is that blood pressure ≥140/90 mm Hg 
should lead to direct initiation of antihypertensive drugs.35 
Hypertension is defined as blood pressure ≥140/90 mm Hg; 
however, in Norway, lifestyle modification is encouraged 
before starting medical treatment. By replacement of blood 
pressure cut- off from ≥160/100 mm Hg to ≥140/90 mm 
Hg, we found that the proportion eligible for interven-
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13.8 percentage points, and when using NORRISK 2 and 
the 2017 guidelines, the proportion eligible for interven-
tion increased by 13.4 percentage points. However, in the 
important debate regarding treatment target in blood pres-
sure levels in primary prevention, it has been suggested 
that lifestyle modification should be emphasised to a larger 
degree before initiating pharmacological treatment.36
Combining risk score and additional risk factors
To the best of our knowledge, there have been few previous 
studies combining both risk score assessment tools and 
additional guidelines to compare the proportion at risk 
of CVD and eligibility of intervention in a general popula-
tion. A study from Germany used the risk assessment tool 
SCORE Deutschland with additional risk factors (diabetes, 
total cholesterol ≥8 mmol/L, renal insufficiency and stage 
3 hypertension (blood pressure ≥180/110 mm Hg)) and 
found 13.4% of the study population to be at high risk of 
10- year CVD mortality.37 Interestingly, the authors found 
that among men, the majority of high- risk individuals were 
eligible for intervention because of SCORE ≥5%, contrary 
to women where the majority of women were classified as 
high risk based on additional risk factors,37 which is in line 
with our findings. Other studies have also found that adding 
comorbidities and single risk factors increases the propor-
tion of individuals at high risk, demonstrating the challenge 
of comparing our findings with other studies.38 39
In conclusion, we found that updated CVD primary 
prevention guidelines increased the proportion at risk and 
eligible for intervention by 3.4 percentage points in individ-
uals aged 40–69 years, where the increase was 3.0 percentage 
points in women and 3.8 percentage points in men. In 
Norway, there are about 2.1 million inhabitants aged 40–69 
years.40 Therefore, this increase causes almost 70 000 more 
individuals eligible for intervention using NORRISK 2 and 
the 2017 guidelines in this age group. Individuals identified 
to be at high risk and eligible for intervention may be given 
the opportunity from their primary physician to make neces-
sary lifestyle changes. The guideline13 suggests that individ-
uals at high risk are given 3–12 months to make changes 
such as smoking cessation, increased physical activity and 
dietary changes to lower blood pressure and cholesterol 
levels before considering initiating drug treatment with anti-
hypertensives and/or lipid- lowering drugs. However, among 
individuals with very high blood pressure, cholesterol levels 
or high total risk, drug treatment may be initiated directly. 
An increase of 3.4 percentage points means a higher number 
of individuals in need of time from their primary physician 
to give lifestyle advice, follow up the effect of this advice and 
assess whether to start drug treatment. Among individuals 
that start drug treatment, there is a need for follow- up to 
evaluate drug efficacy and whether treatment targets are 
achieved, as well as side effects. Change in the guidelines of 
CVD prevention may lead to a higher burden of the health-
care system, but this also translates into a higher number 
of individuals who can avoid a fatal or non- fatal event of 
CVD. The main goal in the use of risk assessment tools is to 
identify the right individuals to keep the balance between 
avoiding the potential negative effects such as side effects, 
overtreatment, undertreatment and a higher cost for the 
healthcare system on one side and preventing high- risk indi-
viduals from developing CVD on the other.2
CONCLUSION
The population proportion eligible for intervention 
increased by 3.4 percentage points from 2009 to 2017 using 
the revised NORRISK 2 score and guidelines, where the 
lowering of threshold in total cholesterol and specified cut- 
off for LDL cholesterol stand for a large proportion of the 
increase in population at risk.
Strengths and limitations
A strength of this study is the use of a sample from a large 
population- based study, with validated endpoints for 
exclusion of prevalent cases and risk factor measurements 
performed by trained personnel using standardised proto-
cols and instruments. A limitation is that participants in 
population- based studies in general tend to be healthier 
than non- attenders. This potential selection bias might 
cause underestimation of the true population proportion in 
need of intervention.
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